A study by Dana-Farber researchers suggests that adding venetoclax to a reduced-intensity drug regimen prior to stem cell transplant can increase the chances of transplant success. The treatment has been found to be safe and does not impair donor cells' ability to engraft in recipients.
Associate Professor Nina Lock's project aims to create a metal-organic sponge that can convert CO2 into useful products such as fuel or building blocks. The research team plans to develop scalable catalysts using cheap elements, investigating the atomic level process of electro-catalysis.
A study of 4,714 adult women found that those with good exercise capacity were at lower risk of death from cardiovascular disease, cancer, and other causes. Women with poor exercise capacity had nearly four times higher annual rates of death from these causes compared to those with good exercise capacity.
The E1912 follow-up analysis shows that ibrutinib-based therapy lived longer and with sustained benefit in previously untreated CLL patients. The majority of patients were well-tolerated, with only 14% stopping due to side effects.
The University of Oklahoma is leading a $2.5 million research project to investigate avian influenza virus diversity and transmission. The project aims to improve surveillance and pandemic preparedness by training researchers and engaging the public in disease ecology and evolution.
A global trial found mosunetuzumab, an off-the-shelf antibody, can induce complete responses in patients with relapsed or refractory non-Hodgkin lymphoma. Higher doses of the drug correlate with patient responses, and remissions appear to be long-lasting.
Researchers identified genetic mutations that predict patient outcomes after a stem cell transplant for acute myeloid leukemia (AML) in patients over age 60. Patients with specific gene mutations were classified into low, high, or intermediate-risk groups, enabling personalized treatment approaches.